India's drug price control regime covers ceiling prices but leaves trade margins largely unregulated. Critically examine in light of recent Supreme Court observations.

Drug prices in India are regulated by the Drugs (Prices Control) Order (DPCO), 2013. Under it, the National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices only for the National List of Essential Medicines (NLEM) drugs placed in Schedule-I [2][3]. In September 2026, the Supreme Court called a ~10-fold mark-up on a cancer drug "carnage": the drug reached retailers at ~₹3,000 and was sold at ~₹27,000 [1]. The case shows that capping the final price is not the same as controlling the margin.

Strengths of the existing regime

• Wide ceiling coverage: ceiling prices exist for 930 scheduled formulations, including 131 anti-cancer drugs [2].
• Guardrail on non-scheduled drugs: under para 20, a drug's MRP cannot rise more than 10% in 12 months, and NPPA monitors for overcharging [4].
• A proven tool: Trade Margin Rationalisation (TMR) put a 30% cap on the trade margin of 42 non-scheduled anti-cancer drugs. MRPs of 526 brands fell by up to 90%, saving patients ~₹984 crore a year [5].

Weaknesses exposed by the Court

• A ceiling is not a margin cap: the ceiling limits the MRP, not the gap between the retailer's buying price (PTR) and the MRP. Firms therefore compete by giving chemists bigger margins, not by charging patients less [1].
• Non-scheduled blind spot: the 10% rule limits how fast prices rise, not how high they start. Drugs such as the statin Rosuvas stay outside the ceiling [1][4].
• Market-based pricing: ceilings are worked out from market prices, so MRPs that are already inflated carry forward into the cap [2].
• Selective use: TMR is applied case by case. DPCO's 16% retailer margin does not apply to all drugs, which is why the Bench asked the Centre why it should not [1].
• Fiscal burden: the government's share of total health spending rose from 29% to 48% between 2014-15 and 2021-22 [6]. Inflated MRPs are now paid increasingly from public funds; as the Bench said, "the loser is the taxpayer" [1].

Counter-view

• Setting prices is the job of the executive and its expert body. A flat 16% margin could make cold-chain or rural stocking unviable. The answer is margins set by product type, not unlimited margins.

Way forward

• Extend TMR to all essential non-scheduled drugs, with a reasoned margin schedule placed before the Court.
• Scale up Jan Aushadhi Kendras (18,000+ outlets selling generics 50–80% cheaper), especially near cancer hospitals [7].

The ceiling-price regime has cut prices, but leaving margins unregulated lets mark-ups continue within the law. Rational, product-specific margin caps, combined with more generics, would make medicines affordable without hurting supply. This would give effect to the right to health under Article 21 and to SDG 3.8 on financial protection.